Twin Tree Management, LP Biomarin Pharmaceutical Inc Put Options Transaction History

Twin Tree Management, LP

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 12, 2024	SELL	$69.02 - $93.84 $773,024 - $1.05 Million	-11,200 Reduced 63.64%	6,400 $449,000
Q2 2024 Aug 13, 2024	SELL	$74.43 - $92.22 $13.8 Million - $17.1 Million	-185,200 Reduced 91.32%	17,600 $1.45 Million
Q1 2024 May 09, 2024	BUY	$83.81 - $99.0 $17 Million - $20.1 Million	202,800 New	202,800 $17.7 Million
Q1 2022 May 11, 2022	SELL	$74.28 - $92.69 $118,848 - $148,304	-1,600 Reduced 13.79%	10,000 $771,000
Q4 2021 Feb 10, 2022	BUY	$71.72 - $91.47 $430,320 - $548,820	6,000 Added 107.14%	11,600 $1.03 Million
Q3 2021 Nov 12, 2021	SELL	$74.77 - $85.47 $29,908 - $34,188	-400 Reduced 6.67%	5,600 $433,000
Q1 2021 May 17, 2021	BUY	$74.73 - $90.69 $112,095 - $136,035	1,500 Added 33.33%	6,000 $453,000
Q4 2020 Feb 12, 2021	SELL	$72.61 - $90.2 $363,050 - $451,000	-5,000 Reduced 52.63%	4,500 $395,000
Q3 2020 Nov 13, 2020	BUY	$71.87 - $131.03 $682,765 - $1.24 Million	9,500 New	9,500 $723,000
Q2 2018 Aug 08, 2018	SELL	$76.01 - $99.03 $152,020 - $198,060	-2,000 Closed	0 $0
Q1 2018 May 09, 2018	BUY	$77.67 - $92.63 $155,340 - $185,260	2,000 New	2,000 $162,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Twin Tree Management, LP, based on Form 13F filings with the SEC.

Stay updated on Twin Tree Management, LP with notifications on news.